查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1954347

癌症干细胞市场分析及预测（至2035年）：按类型、产品类型、服务、技术、应用、最终用户、流程、设备、解决方案划分

Cancer Stem Cells Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Application, End User, Process, Device, Solutions
出版日期: | 出版商: Global Insight Services | 英文 300 Pages | 商品交期: 3-5个工作天内

价格
简介目录

预计癌症干细胞市场规模将从2024年的39亿美元成长到2034年的84亿美元，复合年增长率约为7.3%。癌症干细胞市场主要关注肿瘤内部存在的、具有自我更新能力并驱动癌症进展和转移的细胞。该市场涵盖靶向这些细胞的治疗方法，旨在预防肿瘤復发并改善治疗效果。生物技术的进步和癌症发病率的上升正在推动市场成长，凸显了开发创新治疗方法和个人化医疗方法来有效抑制癌症干细胞的必要性。

受癌症研究和标靶治疗进展的推动，癌症干细胞市场预计将迎来显着成长。以细分市场来看，治疗领域表现最为突出，尤其是在单株抗体和小分子抑制剂方面。这些治疗方法对于针对癌症干细胞路径至关重要，并已展现出令人瞩目的治疗效果。诊断领域也紧随其后，生物标记识别和影像技术在早期检测和个人化治疗策略中发挥关键作用。基于细胞的检测领域发展势头强劲，反映出体外检测和药物筛检的需求日益增长。此外，将传统疗法与新型癌症干细胞标靶疗法结合的联合治疗的兴起也值得关注。这一趋势推动了市场向综合治疗方法的转变。生物製药公司与研究机构之间的研发投入和合作正在加速创新，并为这个不断变化的环境中的相关人员带来盈利的机会。

市场区隔
类型 细胞类型，肿瘤类型
产品 细胞株、设备、耗材和试剂盒
服务 细胞培养服务、生物银行服务、冷冻保存
科技 细胞分离技术、细胞分析技术
应用领域 研究、临床研究、转化研究、药物发现
最终用户 生技公司、製药公司、研究机构、医院和诊所
过程 体内、体外、体外
装置 细胞分选装置，流式细胞仪
解决方案 癌症干细胞检测、癌症干细胞标记物

癌症干细胞市场正经历动态变化，市场份额因定价策略和创新产品的推出而波动。各公司一方面寻求透过具竞争力的价格来扩大市场份额，另一方面也透过新产品的推出来拓展治疗选择。市场格局的特点是研发投入激增，旨在提高治疗效果和改善患者预后，这推动了市场显着增长，越来越多的产品平臺等候核准。策略联盟和合作进一步加速了市场发展势头，并为先进的癌症干细胞疗法铺平了道路。在竞争基准方面，成熟企业正利用其丰富的产品系列来维持竞争优势。新兴企业则凭藉创新技术和策略联盟进入市场。监管的影响至关重要，严格的指导方针影响产品开发和市场准入。北美和欧洲由于拥有有利的法规结构而处于领先地位，而亚太地区则在不断增长的投资和政府扶持政策的推动下，正崛起为一个盈利的市场。竞争格局高度分散，研发的持续进步正在推动市场向前发展。市场参与企业正专注于策略性併购，以扩大其全球企业发展。

主要趋势和驱动因素：

癌症干细胞市场正经历变革性成长，这主要得益于癌症研究和个人化医疗的进步。一个关键趋势是，人们越来越关注专门针对癌症干细胞的标靶治疗，这有望带来更有效的治疗效果。基因组学和蛋白​​质组学的技术进步为这一转变提供了支持，这些技术进步使我们对癌症干细胞的生物学特性有了更深入的了解。此外，全球癌症发生率的不断上升也推动了市场需求。随着癌症发病率的持续增长，人们越来越迫切地需要创新治疗方法来提高存活率和生活品质。另一个驱动因素是公共和私营部门对癌症研究投入的不断增加，这正在促进新型治疗方法的开发。此外，生物技术公司和学术机构之间的合作正在加速研究成果向临床应用的转化。这些伙伴关係对于克服药物开发和监管核准的挑战至关重要。市场也见证了旨在扩大产品系列和增强研发能力的策略联盟和併购活动的增加。人们对癌症干细胞的认识不断加深，为企业开发突破性治疗方法创造了众多机会，这些疗法将重新定义癌症治疗模式。

目录

第一章执行摘要

第二章 市集亮点

第三章 市场动态

  • 宏观经济分析
  • 市场趋势
  • 市场驱动因素
  • 市场机会
  • 市场限制
  • 复合年均成长率：成长分析
  • 影响分析
  • 新兴市场
  • 技术蓝图
  • 战略框架

第四章 细分市场分析

  • 市场规模及预测：依类型
    • 按细胞类型
    • 肿瘤类型
  • 市场规模及预测：依产品划分
    • 细胞株
    • 装置
    • 消耗品
    • 成套工具
  • 市场规模及预测：依服务划分
    • 细胞培养服务
    • 生物银行服务
    • 冷冻保存
  • 市场规模及预测：依技术划分
    • 细胞分离技术
    • 细胞分析技术
  • 市场规模及预测：依应用领域划分
    • 出于研究目的
    • 临床应用
    • 转化研究
    • 药物发现
  • 市场规模及预测：依最终用户划分
    • 生技公司
    • 製药公司
    • 研究所
    • 医院和诊所
  • 市场规模及预测：依製程划分
    • In vivo
    • 体外
    • Ex Vivo
  • 市场规模及预测：依设备划分
    • 细胞分选装置
    • 流式细胞仪
  • 市场规模及预测：按解决方案划分
    • 癌症干细胞检测
    • 癌症干细胞标记物

第五章 区域分析

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地区
  • 亚太地区
    • 中国
    • 印度
    • 韩国
    • 日本
    • 澳洲
    • 台湾
    • 亚太其他地区
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 义大利
    • 其他欧洲地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非
    • 撒哈拉以南非洲
    • 其他中东和非洲地区

第六章 市场策略

  • 需求与供给差距分析
  • 贸易和物流限制
  • 价格、成本和利润率趋势
  • 市场渗透率
  • 消费者分析
  • 法规概述

第七章 竞争讯息

  • 市场定位
  • 市场占有率
  • 竞争基准
  • 主要企业的策略

第八章 公司简介

  • Stemline Therapeutics
  • Onco Med Pharmaceuticals
  • Verastem
  • Asterias Biotherapeutics
  • Stemcentrx
  • Oncolys Bio Pharma
  • Caladrius Biosciences
  • Cytori Therapeutics
  • Epicent Rx
  • Tiziana Life Sciences
  • Immuno Cellular Therapeutics
  • Oryzon Genomics
  • Bio Time
  • Epizyme
  • Karyopharm Therapeutics
  • Fortress Biotech
  • Neuralstem
  • Bio Eclipse Therapeutics
  • Agenus
  • Cellectar Biosciences

第九章：关于我们

简介目录
Product Code: GIS26484

Cancer Stem Cells Market is anticipated to expand from $3.9 billion in 2024 to $8.4 billion by 2034, growing at a CAGR of approximately 7.3%. The Cancer Stem Cells Market focuses on cells within tumors that possess the ability to self-renew and drive cancer progression and metastasis. This market encompasses therapies targeting these cells to prevent tumor recurrence and improve treatment efficacy. Advances in biotechnology and increasing cancer prevalence drive market growth, emphasizing the need for innovative treatments and personalized medicine approaches to effectively combat cancer stem cells.

The Cancer Stem Cells Market is poised for significant growth, driven by advancements in cancer research and targeted therapies. Among the segments, the therapeutics sub-segment emerges as a top performer, particularly in monoclonal antibodies and small molecule inhibitors. These therapies are pivotal in targeting cancer stem cell pathways, offering promising treatment outcomes. The diagnostics sub-segment follows closely, with biomarker identification and imaging technologies playing a crucial role in early detection and personalized treatment strategies. The cell-based assays segment is gaining momentum, reflecting the increasing demand for in vitro testing and drug screening. Furthermore, the rise of combination therapies, integrating traditional treatments with novel cancer stem cell-targeted approaches, is noteworthy. This trend underscores the market's shift towards comprehensive treatment regimens. Investments in R&D and collaborations between biopharmaceutical companies and research institutions are accelerating innovation, highlighting lucrative opportunities for stakeholders in this evolving landscape.

Market Segmentation
TypeCell Type, Tumor Type
ProductCell Lines, Instruments, Consumables, Kits
ServicesCell Culture Services, Biobanking Services, Cryopreservation
TechnologyCell Separation Technology, Cell Analysis Technology
ApplicationResearch Applications, Clinical Applications, Translational Research, Drug Discovery
End UserBiotechnology Companies, Pharmaceutical Companies, Research Institutes, Hospitals and Clinics
ProcessIn Vivo, In Vitro, Ex Vivo
DeviceCell Sorters, Flow Cytometers
SolutionsCancer Stem Cell Assays, Cancer Stem Cell Markers

The Cancer Stem Cells Market is witnessing a dynamic shift, with market share being influenced by pricing strategies and innovative product launches. Companies are focusing on competitive pricing to capture a larger share, while new product launches are enhancing therapeutic options. The market landscape is characterized by a surge in research and development, aimed at improving treatment efficacy and patient outcomes. This has led to a robust pipeline of products awaiting regulatory approval, positioning the market for significant growth. The strategic alliances and collaborations are further driving market momentum, paving the way for advanced cancer stem cell therapies. In terms of competition benchmarking, established players are leveraging their extensive portfolios to maintain a competitive edge. Emerging companies are entering the market with novel technologies and strategic partnerships. Regulatory influences are pivotal, with stringent guidelines impacting product development and market entry. North America and Europe are at the forefront due to favorable regulatory frameworks, while Asia-Pacific is emerging as a lucrative market, driven by increasing investments and supportive government policies. The competitive landscape is highly fragmented, with continuous advancements in research propelling the market forward. Market participants are focusing on strategic mergers and acquisitions to expand their global footprint.

Geographical Overview:

The Cancer Stem Cells Market is witnessing dynamic growth across various regions, each presenting unique opportunities. North America leads, driven by advanced research facilities and substantial investments in biotechnology. The presence of major pharmaceutical companies further accelerates market expansion. Europe follows, with robust government support for cancer research and a strong focus on innovative therapies. The region's regulatory framework enhances market growth. In Asia Pacific, rapid economic development and increasing healthcare expenditure fuel market expansion. Countries like China and India are emerging as key players, investing heavily in cancer research. The growing prevalence of cancer in these regions also drives demand. Latin America and the Middle East & Africa are nascent markets with significant potential. In Latin America, improved healthcare infrastructure and rising awareness contribute to market growth. Meanwhile, the Middle East & Africa are recognizing the importance of investing in advanced cancer treatments to improve patient outcomes.

Global tariffs and geopolitical tensions are profoundly impacting the Cancer Stem Cells Market, particularly in Japan, South Korea, China, and Taiwan. Japan and South Korea are enhancing their biopharmaceutical capabilities to mitigate reliance on imports, while China is accelerating its domestic R&D to counteract Western restrictions. Taiwan, though a key player in biotech, faces geopolitical vulnerabilities. The global parent market for cancer treatments is robust, driven by technological advancements and increasing cancer incidences. By 2035, the market is anticipated to witness substantial growth, contingent upon strategic alliances and innovation. Concurrently, Middle East conflicts are influencing global supply chains, potentially escalating energy prices and impacting manufacturing costs across these nations, necessitating strategic energy procurement and supply chain resilience.

Key Trends and Drivers:

The Cancer Stem Cells Market is experiencing transformative growth, driven by advancements in cancer research and personalized medicine. A key trend is the increasing focus on targeted therapies that specifically address cancer stem cells, promising more effective treatment outcomes. This shift is supported by technological advancements in genomics and proteomics, enabling deeper insights into cancer stem cell biology. Additionally, the rising prevalence of cancer globally is propelling market demand. As cancer incidence continues to climb, there is a heightened urgency for innovative treatments that can improve survival rates and quality of life. Another driver is the growing investment in cancer research by both public and private sectors, fueling the development of novel therapeutic approaches. Furthermore, collaborations between biotech companies and academic institutions are accelerating the translation of research findings into clinical applications. These partnerships are pivotal in overcoming the challenges associated with drug development and regulatory approvals. The market is also witnessing an increase in strategic alliances and mergers, aimed at expanding product portfolios and enhancing R&D capabilities. As the understanding of cancer stem cells evolves, opportunities abound for companies to develop groundbreaking therapies that could redefine cancer treatment paradigms.

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Application
  • 2.6 Key Market Highlights by End User
  • 2.7 Key Market Highlights by Process
  • 2.8 Key Market Highlights by Device
  • 2.9 Key Market Highlights by Solutions

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Cell Type
    • 4.1.2 Tumor Type
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Cell Lines
    • 4.2.2 Instruments
    • 4.2.3 Consumables
    • 4.2.4 Kits
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Cell Culture Services
    • 4.3.2 Biobanking Services
    • 4.3.3 Cryopreservation
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 Cell Separation Technology
    • 4.4.2 Cell Analysis Technology
  • 4.5 Market Size & Forecast by Application (2020-2035)
    • 4.5.1 Research Applications
    • 4.5.2 Clinical Applications
    • 4.5.3 Translational Research
    • 4.5.4 Drug Discovery
  • 4.6 Market Size & Forecast by End User (2020-2035)
    • 4.6.1 Biotechnology Companies
    • 4.6.2 Pharmaceutical Companies
    • 4.6.3 Research Institutes
    • 4.6.4 Hospitals and Clinics
  • 4.7 Market Size & Forecast by Process (2020-2035)
    • 4.7.1 In Vivo
    • 4.7.2 In Vitro
    • 4.7.3 Ex Vivo
  • 4.8 Market Size & Forecast by Device (2020-2035)
    • 4.8.1 Cell Sorters
    • 4.8.2 Flow Cytometers
  • 4.9 Market Size & Forecast by Solutions (2020-2035)
    • 4.9.1 Cancer Stem Cell Assays
    • 4.9.2 Cancer Stem Cell Markers

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Application
      • 5.2.1.6 End User
      • 5.2.1.7 Process
      • 5.2.1.8 Device
      • 5.2.1.9 Solutions
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Application
      • 5.2.2.6 End User
      • 5.2.2.7 Process
      • 5.2.2.8 Device
      • 5.2.2.9 Solutions
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Application
      • 5.2.3.6 End User
      • 5.2.3.7 Process
      • 5.2.3.8 Device
      • 5.2.3.9 Solutions
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Application
      • 5.3.1.6 End User
      • 5.3.1.7 Process
      • 5.3.1.8 Device
      • 5.3.1.9 Solutions
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Application
      • 5.3.2.6 End User
      • 5.3.2.7 Process
      • 5.3.2.8 Device
      • 5.3.2.9 Solutions
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Application
      • 5.3.3.6 End User
      • 5.3.3.7 Process
      • 5.3.3.8 Device
      • 5.3.3.9 Solutions
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Application
      • 5.4.1.6 End User
      • 5.4.1.7 Process
      • 5.4.1.8 Device
      • 5.4.1.9 Solutions
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Application
      • 5.4.2.6 End User
      • 5.4.2.7 Process
      • 5.4.2.8 Device
      • 5.4.2.9 Solutions
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Application
      • 5.4.3.6 End User
      • 5.4.3.7 Process
      • 5.4.3.8 Device
      • 5.4.3.9 Solutions
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Application
      • 5.4.4.6 End User
      • 5.4.4.7 Process
      • 5.4.4.8 Device
      • 5.4.4.9 Solutions
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Application
      • 5.4.5.6 End User
      • 5.4.5.7 Process
      • 5.4.5.8 Device
      • 5.4.5.9 Solutions
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Application
      • 5.4.6.6 End User
      • 5.4.6.7 Process
      • 5.4.6.8 Device
      • 5.4.6.9 Solutions
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Application
      • 5.4.7.6 End User
      • 5.4.7.7 Process
      • 5.4.7.8 Device
      • 5.4.7.9 Solutions
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Application
      • 5.5.1.6 End User
      • 5.5.1.7 Process
      • 5.5.1.8 Device
      • 5.5.1.9 Solutions
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Application
      • 5.5.2.6 End User
      • 5.5.2.7 Process
      • 5.5.2.8 Device
      • 5.5.2.9 Solutions
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Application
      • 5.5.3.6 End User
      • 5.5.3.7 Process
      • 5.5.3.8 Device
      • 5.5.3.9 Solutions
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Application
      • 5.5.4.6 End User
      • 5.5.4.7 Process
      • 5.5.4.8 Device
      • 5.5.4.9 Solutions
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Application
      • 5.5.5.6 End User
      • 5.5.5.7 Process
      • 5.5.5.8 Device
      • 5.5.5.9 Solutions
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Application
      • 5.5.6.6 End User
      • 5.5.6.7 Process
      • 5.5.6.8 Device
      • 5.5.6.9 Solutions
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Application
      • 5.6.1.6 End User
      • 5.6.1.7 Process
      • 5.6.1.8 Device
      • 5.6.1.9 Solutions
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Application
      • 5.6.2.6 End User
      • 5.6.2.7 Process
      • 5.6.2.8 Device
      • 5.6.2.9 Solutions
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Application
      • 5.6.3.6 End User
      • 5.6.3.7 Process
      • 5.6.3.8 Device
      • 5.6.3.9 Solutions
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Application
      • 5.6.4.6 End User
      • 5.6.4.7 Process
      • 5.6.4.8 Device
      • 5.6.4.9 Solutions
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Application
      • 5.6.5.6 End User
      • 5.6.5.7 Process
      • 5.6.5.8 Device
      • 5.6.5.9 Solutions

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Stemline Therapeutics
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Onco Med Pharmaceuticals
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Verastem
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Asterias Biotherapeutics
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Stemcentrx
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Oncolys Bio Pharma
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Caladrius Biosciences
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Cytori Therapeutics
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Epicent Rx
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Tiziana Life Sciences
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Immuno Cellular Therapeutics
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Oryzon Genomics
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Bio Time
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Epizyme
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Karyopharm Therapeutics
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Fortress Biotech
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Neuralstem
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Bio Eclipse Therapeutics
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Agenus
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Cellectar Biosciences
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us